DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient

Information source: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV Infections

Intervention: Oxazepam (Drug); Zidovudine (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)

Official(s) and/or principal investigator(s):
Israelski D, Study Chair
Blaschke T, Study Chair

Summary

To determine if a pharmacokinetic (blood level) interaction exists between zidovudine (AZT) and oxazepam in the HIV-infected patient. Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. This study is important because of the potential for toxicity resulting from a reaction between AZT and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with HIV infection.

Clinical Details

Official title: The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient

Study design: Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment

Detailed description: Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. This study is important because of the potential for toxicity resulting from a reaction between AZT and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with HIV infection. Patients are studied to determine oral and intravenous AZT and single oral dose oxazepam pharmacokinetics. Patients then take AZT and oxazepam together to determine if interactions between the drugs occur.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria Concurrent Medication: Required:

- Stable prescribed dosage of zidovudine (AZT), = or > 500 mg/day.

Allowed:

- Prophylaxis for Pneumocystis carinii pneumonia (PCP) with aerosolized pentamidine.

- Erythropoietin.

Patients must be:

- HIV positive by ELISA and Western blot.

- Currently taking a stable prescribed dosage of 500 mg/day of zidovudine (AZT).

Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded:

- Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT)

therapy of = or < 600 mg/day.

- Significant underlying medical condition that could impair continuous participation

in study.

- Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated

with an unintentional weight loss of at least 10 percent of body weight). Concurrent Medication: Excluded:

- Oral contraceptives.

- Cytotoxic chemotherapy.

- Ganciclovir.

- Flucytosine.

- Probenecid.

- Opiates.

- Valproic acid.

- Sulfa drugs.

- Sucralfate.

- Dapsone.

- Rifampin.

- Antacids within 2 hours of zidovudine (AZT) dose.

- Isoniazid.

- Ketoconazole.

- Pyrimethamine.

- Clindamycin.

- Aspirin.

- Ibuprofen.

- Investigational drugs not specifically allowed.

Patients with the following are excluded:

- Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT)

therapy of = or < 600 mg/day.

- Significant underlying medical condition that could impair continuous participation

in study.

- Unable to take oral medication reliably.

Prior Medication: Excluded within 30 days of study entry:

- Antiretroviral agents other than zidovudine (AZT).

Locations and Contacts

Palo Alto Veterans Adm Med Ctr / Stanford Univ, Palo Alto, California 94304, United States
Additional Information

Click here for more information about Zidovudine

Related publications:

Mole LA, Israelski DM, Bubp JL, O'Hanley P, Merigan T, Blaschke T. The pharmacokinetics (PK) of zidovudine (ZDV) and oxazepam (OXA) alone and in combination in the HIV-infected patient (ACTG 124). Int Conf AIDS. 1992 Jul 19-24;8(2):B186 (abstract no PoB 3595)

Mole L, Israelski D, Bubp J, O'Hanley P, Merigan T, Blaschke T. Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. J Acquir Immune Defic Syndr. 1993 Jan;6(1):56-60.


Last updated: August 1, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017